Pharmafile Logo
Pharmafocus logo
Advanced Search

Xtandi

Showing 7 posts of 22 posts found.

sir michael parkinson image

Sir Michael Parkinson criticises NICE

February 4, 2014
Medical Communications, Sales and Marketing Astellas, NHS, NICE, Xtandi, parkinson, prostate

TV host Sir Michael Parkinson has told NICE that it must lift the restrictions imposed on Astellas’ new prostate cancer …

News

NICE looks at Xtandi again

January 28, 2014
Sales and Marketing Astellas, NHS, NICE, Xtandi

NICE has announced it is to consult again on its decision to recommend Astellas Pharma’s prostate cancer drug Xtandi after …

News

Astellas seeks Xtandi extension

December 5, 2013
Sales and Marketing Astellas, Cancer, EU, FDA, US, Xtandi

Astellas Pharma and development partner Medivation are seeking to extend the reach of oncology brand Xtandi by conducting a trial …

News
Xofigo

Bayer cancer drug gets EU approval

November 18, 2013
Sales and Marketing Bayer, CHMP, EU, Xtandi, Zytiga, xofigo

Bayer’s prostate cancer treatment Xofigo has been shown the green light by the European Commission.  Xofigo (radium Ra 223 dichloride) …

News

Astellas gets NICE nod

October 18, 2013
Sales and Marketing Cancer, NHS, NICE, Xtandi

Astellas Pharma’s new prostate cancer drug Xtandi which has been shown to shrink and kill cancer cells, has been recommended …

News

Xtandi gets EU approval

June 26, 2013
Sales and Marketing Astellas, FDA, Xtandi

Astellas Pharma’s Xtandi has been approved in the European Union for the treatment of adult men with advanced prostate cancer, …

News

Prostate cancer drug Xtandi gets nod

April 26, 2013
Sales and Marketing Xtandi, Zytiga, prostate cancer

Astellas and Medivation have received a positive opinion from Europe’s Committee for Medicinal Products for Human Use (CHMP) for Xtandi, …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026